PPD, Inc.

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Retrieved on: 
Tuesday, April 9, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Internal medicine, Incretin, Obesity, AstraZeneca, Novo Nordisk, Cardiology, University college, Patient, DSM-IV codes, Weight loss, NAMS, Doctor of Philosophy, MD, Biology, PPD, Inc., Book, Ageing, Pharmaceutical industry

BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors.

Key Points: 
  • BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors.
  • "We are delighted to welcome Michael to BioAge's board of directors," said Kristen Fortney, PhD, CEO and co-founder of BioAge Labs.
  • "I'm excited to join the board of BioAge at this pivotal juncture, as the company progresses azelaprag into Phase 2 trials in obesity," said Davidson.
  • I look forward to working with the team to bring this promising therapy to patients in need."

Contract Research Organization (CRO) Market size to grow by USD 63.35 billion from 2024-2028, Market Growth at 12.61% CAGR expected during the forecast period, Technavio

Retrieved on: 
Wednesday, March 20, 2024
ChromeOS, Software as a service, Science, Chronic condition, Infection, Laboratory, Clinical trial, European, USD, Regulation, Obesity, Biotechnology, Risk, Diabetes, CNS, DSM-IV codes, ROW, Contract research organization, Compound annual growth rate, TB, PPD, Central nervous system disease, Neurology, Medicine, Medication, Clinical, Science 37, Research, Acquisition, Cancer, Drug development, HIV/AIDS, DCT, Growth, Cardiology, Software, Messenger, Behavior, PPD, Inc., Malaria, Lung compliance, Fine chemical

By geography, the global contract research organization (cro) market is segmented into North America, Europe, Asia, and Rest of World (ROW).

Key Points: 
  • By geography, the global contract research organization (cro) market is segmented into North America, Europe, Asia, and Rest of World (ROW).
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global contract research organization (cro) market.
  • Growth of the Contract Research Organization (CRO) Market industry across North America, Europe, Asia, and Rest of World (ROW)
    Gain instant access to 17,000+ market research reports.
  • The global mRNA synthesis raw material market size is estimated to grow by USD 776.45 million at a CAGR of 4.93% between 2023 and 2028.

Krishna K. Maridi Joins Sonrava Health as Chief Financial Officer

Retrieved on: 
Tuesday, July 11, 2023
General Health, Other Health, Health, Dental, Optical, PPD, International, CFA, Capital market, Skin care, PPD, Inc., Pfizer, Dentistry, Thermo Fisher Scientific, COVID, DSO, Chartered Financial Analyst, Sale, Business administration, Pilani, CFO, Master of Business Administration, Chemical engineering, Maridi, Institute of Chartered Financial Analysts of India, Management

Krishna K. Maridi has joined Sonrava Health as Chief Financial Officer (CFO) effective July 10.

Key Points: 
  • Krishna K. Maridi has joined Sonrava Health as Chief Financial Officer (CFO) effective July 10.
  • Sonrava Health is a national family of health and wellness companies – including differentiated dental office brands, dental and vision benefit plans, provider networks, and consumer products and services – focused on quality, value and innovation.
  • Mr. Maridi comes to Sonrava Health with more than 25 years of US and International financial leadership experience.
  • “We welcome Krishna to the Sonrava Health team,” said Daniel D. Crowley, Chairman and Chief Executive Officer of Sonrava Health.

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

Retrieved on: 
Tuesday, July 11, 2023
Chem, Trinity College, DNA, PPD, MIT Sloan School of Management, Partnership, Biochemistry, Therapy, Doctor of Philosophy, Biotechnology, PPD, Inc., Trust, MBA, Partner (business rank), Trust Company, History, Messenger, Georgetown University, Chemistry, Foreign Service, Acquisition, Patient, ERNA, Brown University, Machine learning, School, Drug discovery, Walsh School of Foreign Service, Juno Therapeutics, Library, Technology transfer, Massachusetts Institute of Technology, Pharmaceutical industry, Management, Film industry, Fine chemical, Eterna

“We are delighted to welcome Brant and Richard to our Board.

Key Points: 
  • “We are delighted to welcome Brant and Richard to our Board.
  • Mr. Binder began his career in venture capital and private equity investment at Trust Company of the West.
  • Richard Wagner, Ph.D., is a biotechnology entrepreneur with more than 30 years of experience creating and managing drug discovery innovations.
  • Both Mr. Binder and Dr. Wagner served in executive operating roles and on the Board of Directors of the foregoing companies.

Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

Retrieved on: 
Tuesday, January 17, 2023
Health, Pharmaceutical, Crest Whitestrips, PPD, Inc., Science, Gurnet Point, Massachusetts, Salix Pharmaceuticals, NYSE, PPD, NDA, Marketing, Ohio State University, Therapy, BS, Patient, PG, Research, Sale, Dementia, GSK, Pain, Fine chemical, Pharmacy, Corium

Corium Pharma Solutions, Inc. (“Corium Pharma Solutions” or “CPSI”), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors.

Key Points: 
  • Corium Pharma Solutions, Inc. (“Corium Pharma Solutions” or “CPSI”), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors.
  • Mark joins Corium Pharma Solutions shortly after its formation in October 2022, when Webster Equity Partners (“Webster”) acquired the standalone business unit from its former, commercial-stage biopharmaceutical parent company, Corium.
  • “I am thrilled to welcome Mark as Chief Executive Officer of Corium Pharma Solutions,” said Travis Wilson, Partner at Gurnet Point.
  • He is uniquely qualified to step into the leadership role and Corium Pharma Solutions will benefit from his deep product development, regulatory, and commercial experience across numerous therapeutics areas.”
    “I am excited to have the opportunity to lead the Corium Pharma Solutions team as we continue to build on the company’s historical successes and further establish its leadership position in transdermal contract development and manufacturing,” said Dr. Mark Sirgo, Chief Executive Officer.

Specimen Containers Market Size, Share & Trends Analysis Report 2022: Polypropylene (PP) Containers Accounted for the Largest Market Share of 45% in 2021 - Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 16, 2022
General Health, Health, Medical Supplies, PP, Collection, Coronavirus, Prevalence, Plastic, Sputum, Thermo Fisher Scientific, Paper, Laboratory, Growth, Urine, Conditional sentence, USD, PPD, PVC, Blood, COVID-19, Patient, PPD, Inc., Recycling, Dentistry, Fine chemical, Vial

The "Specimen Containers Market Size, Share & Trends Analysis Report by Raw Material (Polypropylene, PVC), by Type (Airtight Containers, Vials), by End-user, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Specimen Containers Market Size, Share & Trends Analysis Report by Raw Material (Polypropylene, PVC), by Type (Airtight Containers, Vials), by End-user, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global specimen containers market size is anticipated to reach USD 3.05 billion by 2030, expanding at a CAGR of 4.85% from 2022 to 2030.
  • The increasing prevalence of chronic disorders, technological advancements, and the rising geriatric population are the key factors driving the market.
  • By raw material, polypropylene (PP) accounted for the largest market share of over 45.0% in 2021.

Global Cardiac Safety Services Market Report 2022 to 2027: Growth in Biosimilars and Biologics Markets Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022
Health, Cardiology, Blood pressure, Roe, Richmond Pharmacology, Cros, Clinical trial, LabCorp, Medication, SGS, USD, PPD, Inc., Stand-alone, Growth, Cardiac imaging, Conditional sentence, Drug discovery, Integration, Drug, Incidence, Medical device, Fine chemical, IQVIA, Arbutus Biopharma

The "Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter measurement, Blood Pressure measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical, Biopharma, CROs), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter measurement, Blood Pressure measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical, Biopharma, CROs), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The cardiac safety services market is projected to reach USD 1.0 Billion by 2027 from USD 0.6 Billion in 2022, at a CAGR of 11.2% during the forecast period.
  • Blood pressure monitoring is an essential part of cardiac safety services.
  • It accounted for the second largest market share of the cardiac safety services market.

Thermo Fisher Scientific Unveils New Clinical Research Laboratory in Virginia

Retrieved on: 
Wednesday, October 12, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Other Health, PPD, Applied Biosystems, Thermo Fisher Scientific, Growth, Patheon, Science, Vaccine, Laboratory, GMP, Immunochemistry, Fisher Scientific, Drug development, Research, Workforce, Mindful Scientific Inc., Commonwealth, Drug discovery, Health, Safety, West Pharmaceutical Services, Invitrogen, PPD, Inc., Biomarker, Fine chemical

Thermo Fisher Scientific, the world leader in serving science, today expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, Virginia.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, Virginia.
  • The entire Richmond operation employs about 1,300 local professionals, including Ph.D.-level scientists, analytical laboratory staff and other scientific professionals.
  • The ongoing expansion of our bioanalytical operations builds on the growth of our drug development expertise over nearly four decades, enabling us to provide customers with high-quality lab services to advance their clinical research programs, said David M. Johnston, Ph.D., senior vice president and president, clinical research, Thermo Fisher Scientific.
  • Virginia Governor Glenn Youngkin said, Congratulations to Thermo Fisher on the unveiling of their new clinical research laboratory.

Pharmaceutical Analytical Testing Outsourcing Market to record USD 3.21 Bn growth -- Driven by an increased number of FDA-approved manufacturing facilities in developing nations

Retrieved on: 
Wednesday, September 14, 2022
Dendrite International, Inc. v. Doe No. 3, SA, Segmental analysis (biology), PPD, Inc., FDA, USD, SGS, Intertek, Wuxi, CAGR, Fine chemical

NEW YORK, Sept. 14, 2022 /PRNewswire/ -- The pharmaceutical analytical testing outsourcing market size is expected to grow by USD 3.21 billion, accelerating at a CAGR of 8.15% during the forecast period.

Key Points: 
  • NEW YORK, Sept. 14, 2022 /PRNewswire/ -- The pharmaceutical analytical testing outsourcing market size is expected to grow by USD 3.21 billion, accelerating at a CAGR of 8.15% during the forecast period.
  • The global pharmaceutical analytical testing outsourcing market is fragmented.
  • The market is driven by an increased number of FDA-approved manufacturing facilities in developing nations.
  • The pharmaceutical analytical testing outsourcing market is fragmented, and the degree of fragmentationwill accelerateduring the forecast period.

$119 Billion Worldwide Contract Research and Manufacturing Services Industry to 2031 - Rising Aging Population With Various Chronic Diseases is Expected to Have a Positive Impact - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 13, 2022
Technology, Science, Consumer, Biotechnology, Other Manufacturing, Health, Health Technology, Packaging, Other Science, Chemicals, Plastics, Research, Marketing, Communications, Manufacturing, Pharmaceutical, Seniors, Artificial Intelligence, Benchmark, Safety, CMOS, PPD, Inc., Ageing, Arthritis, Prevalence, Thermo Fisher Scientific, Alzheimer's disease, Create, Catalent, Organization, Population, Acquisition, Growth, Data management, Cros, Maintenance, Diabetes, Clinical trial, Cancer, CRO, Coronavirus, PPD, Drug development, Behavior, Research, Medicine, AbbVie, Conditional sentence, Artificial intelligence, Marketing, Fine chemical, Pharmaceutical industry

The contract research and manufacturing services (CRAMS) market consists of sales of outsourcing services by entities (organizations, sole traders, and partnerships) that provide outsourcing research services or product manufacturing activities from low-cost providers in the form of contract research organization (CROs) and contract manufacturing organizations (CMOS).

Key Points: 
  • The contract research and manufacturing services (CRAMS) market consists of sales of outsourcing services by entities (organizations, sole traders, and partnerships) that provide outsourcing research services or product manufacturing activities from low-cost providers in the form of contract research organization (CROs) and contract manufacturing organizations (CMOS).
  • The main types of services provide by contract research and manufacturing services (CRAMS) are manufacturing and research.
  • Manufacturing services include outsourcing drug development services to companies operating in the pharmaceutical or biotechnology industry on a contract basis.
  • The rising aging population with various chronic diseases is expected to have a positive impact on the growth of the contract research and manufacturing services market in the forecast period.